DILAPAN-S
healthcare economics
Discover how DILAPAN-S could transform labour induction—saving time for healthcare staff, reducing healthcare costs, while enhancing patient care and increasing maternal satisfaction. Learn more about the impact of DILAPAN-S.
![](https://www.dilapan.com/wp-content/uploads/2024/06/heor-hero-img-1024x765.png)
Embrace a non-hormonal approach to labour induction that supports your medical team’s goals and enhances patient satisfaction.
11 %
Total cost savings with outpatient ripening
Up to
10 hours
of hospitalisation time saving with outpatient ripening
2.4 hours
Midwife time saved per IOL
Only 1 %
of the total IOL cost is the cost of the ripening agent
DILAPAN-S - key contributions to the IOL health economics
![](https://www.dilapan.com/wp-content/uploads/2024/06/time-saving.png)
Time savings
- Reduced workload
- Shorter stay in hospital with outpatient ripening
![](https://www.dilapan.com/wp-content/uploads/2024/06/savings-icon.png)
Cost savings
- Improved resource utilisation
- Optimised patient flow
![](https://www.dilapan.com/wp-content/uploads/2024/06/beneftis-efficacy.png)
Improved patient care
- Superior maternal satisfaction
- Significantly decreased analgesia requirements
Inpatient cervical ripening with DILAPAN-S
is cost-equivalent to the dinoprostone vaginal insert, whilst additionally saving 2.4 hours per induction of labour.
![](https://www.dilapan.com/wp-content/uploads/2024/06/time-saving.png)
Time savings
- Reduced monitoring time
- Lower rate of hyperstimulation
- Significantly less analgesia requirements
Using data from SOLVE randomised clinical trial, a UK cost-consequence model compared two induction methods recommended by clinical guidelines (incl. NICE guideline): DILAPAN-S and dinoprostone vaginal insert.
One of the key conclusions is that DILAPAN-S offers a time saving of up to 2.4 hours per induction.
![](https://www.dilapan.com/wp-content/uploads/2024/06/time-savings2-1024x672.png)
![](https://www.dilapan.com/wp-content/uploads/2024/06/beneftis-efficacy.png)
Cost neutrality
- The methods were evaluated as cost neutral
- DILAPAN-S offers savings during ripening phase
- Increased need for oxytocin augmentation may affect cost of active phase of labour
Clinical feedback suggests that there is a significant variation between hospitals in the frequency of oxytocin need. Clinical research into ways of reducing the use of oxytocin after successful mechanical cervical ripening (e.g. mobilisation of induced women) may provide a new clinical data to further optimise patient care.
![](https://www.dilapan.com/wp-content/uploads/2024/06/cost-neutrality2-1024x446.png)
Are you interested in data from US?
Discover economic insights related to DILAPAN-S in the US market here.
![](https://www.dilapan.com/wp-content/uploads/2024/06/flag-blue-150x150.png)
Outpatient cervical ripening with DILAPAN-S
may provide additional savings and further improve patient care.
![](https://www.dilapan.com/wp-content/uploads/2024/06/benefits-maternity-units.png)
Time saving and reduction of total hospital stay
- Significant saving of around 10 hours from admission to active labour
- Total hospital stay significantly reduced
- Improved patient flow
The outpatient use of DILAPAN-S not only reduces hospital stay but may also increase maternal satisfaction. Importantly, it maintains a safety profile comparable to that of inpatient use.
![](https://www.dilapan.com/wp-content/uploads/2024/06/hospital-stay2-1024x920.png)
![](https://www.dilapan.com/wp-content/uploads/2024/06/savings-icon.png)
Cost savings
- Significantly shorter stay in hospital
- Significantly higher VD24 rate* from admission
- Reduction in analgesia use
The reduction in hospital stay and decreased staff time requirements associated with DILAPAN-S outpatient cervical ripening resulted in significant cost savings.
*VD24 rate—vaginal delivery rate within 24 hours
![](https://www.dilapan.com/wp-content/uploads/2024/06/cost-savings2-1024x582.png)
*VD24 rate—vaginal delivery rate within 24 hours
Are you interested in data from US?
Discover economic insights related to DILAPAN-S in the US market here.
![](https://www.dilapan.com/wp-content/uploads/2024/06/flag-blue-150x150.png)
Upfront cost impact
- The upfront cost of cervical ripening agent represents only around 1% of the total cost
- Cost-effectiveness is usually determined by parameters other than the purchase price of the product itself
![](https://www.dilapan.com/wp-content/uploads/2024/06/graph-1-1024x592.png)
![](http://www.dilapan.com/wp-content/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
What users say
about DILAPAN-S?
Trusted by expectant mothers and doctors around the world.
Healthcare Professional, Lead Midwife, Cardiff UK
Healthcare Professional, Midwife, Nottingham, UK
Healthcare Professional, Consultant obstetrician and gynaecologist, Calderdale, UK
Healthcare Professional, Midwifery Sister, London UK
Healthcare Professional, Midwifery Sister, London UK
Healthcare Professional, Lead Midwife, Cardiff UK
Healthcare Professional, Consultant obstetrician and gynaecologist, Essex, UK
Healthcare Professional, Matron at Royal Surrey, UK
Healthcare Professional, Midwife, North Cumbria, UK
Mother
Mother
Mother
Mother
Navigating DILAPAN-S usage
Learn about DILAPAN-S mode of action, its functionality, and how it integrates into labour induction protocols for effective outcomes.
![](https://www.dilapan.com/wp-content/uploads/2024/06/usage-img-1024x531.png)
Need to know more?
Uncover a wealth of knowledge with our comprehensive resources and detailed FAQs.